AVAH · Aveanna Healthcare Holdings, Inc. · Documents

May 8

Quarterly report 10-Q FY2025 Q1, ended Mar 29

Quarterly report for FY2025 Q1

Revenue $559.22M ▲ 14.0% Net income $5.19M Diluted EPS $0.03

Apr 3

Current report 8-K Events of Apr 1

Unregistered sale of equity, Other events

Mar 28

Current report 8-K Events of Mar 27

Director or officer change, or executive pay

Mar 25

Proxy statement DEF 14A Meeting May 9, 2025

Proxy statement

Mar 25

Annual report to holders ARS

Annual report to holders

Mar 25

Proxy statement DEFA14A

Proxy statement

Mar 14

Current report 8-K

Regulation FD disclosure

Mar 13

Earnings call

Q4 2025 earnings call

Mar 13

Current report 8-K

Financial results, Regulation FD disclosure

Mar 13

Annual report 10-K FY2024, ended Dec 28

Annual report for FY2024

Revenue $2.02B ▲ 6.8% Net loss $10.93M Diluted EPS -$0.06

Dec 31

Earnings call

Q4 2024 earnings call

Nov 8

Current report 8-K

Regulation FD disclosure

Nov 7

Earnings call

Q3 2024 earnings call

Nov 7

Current report 8-K

Financial results, Regulation FD disclosure

Nov 7

Quarterly report 10-Q FY2024 Q3, ended Sep 28

Quarterly report for FY2024 Q3

Revenue $509.02M ▲ 6.5% Net loss $42.84M Diluted EPS -$0.22

Nov 4

Current report 8-K Events of Nov 1

Director or officer change, or executive pay

Oct 4

Current report 8-K Events of Sep 30

Entered into a material agreement, Regulation FD disclosure

Sep 9

Registration statement S-3/A

Registration statement

Sep 6

Registration statement S-3

Registration statement

Aug 9

Current report 8-K

Regulation FD disclosure

Aug 8

Earnings call

Q2 2024 earnings call

Aug 8

Current report 8-K

Financial results, Regulation FD disclosure

Aug 8

Quarterly report 10-Q FY2024 Q2, ended Jun 29

Quarterly report for FY2024 Q2

Revenue $504.96M ▲ 7.0% Net income $13.91M ▼ 45.7% Diluted EPS $0.07 ▼ 46.2%

Jun 5

Current report 8-K Events of May 31

Entered into a material agreement

May 31

Current report 8-K

Regulation FD disclosure

May 17

Current report 8-K Events of May 16

Shareholder vote results

May 10

Current report 8-K

Regulation FD disclosure

May 9

Earnings call

Q1 2024 earnings call

May 9

Current report 8-K

Financial results, Regulation FD disclosure

May 9

Quarterly report 10-Q FY2024 Q1, ended Mar 30

Quarterly report for FY2024 Q1

Revenue $490.65M ▲ 5.2% Net loss $11.17M Diluted EPS -$0.06

Apr 1

Proxy statement DEF 14A Meeting May 16, 2024

Proxy statement

Apr 1

Annual report to holders ARS

Annual report to holders

Apr 1

Proxy statement DEFA14A

Proxy statement

Mar 14

Earnings call

Q4 2023 earnings call

Mar 14

Current report 8-K

Financial results, Regulation FD disclosure

Mar 14

Annual report 10-K FY2023, ended Dec 30

Annual report for FY2023

Revenue $1.9B ▲ 6.0% Net loss $134.52M Diluted EPS -$0.71

Jan 17

Current report 8-K Events of Jan 15

Director or officer change, or executive pay

Dec 11

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Nov 14

Current report 8-K

Regulation FD disclosure

Nov 9

Earnings call

Q3 2023 earnings call

Nov 9

Current report 8-K

Financial results, Regulation FD disclosure

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $478.01M ▲ 7.9% Net loss $102.39M Diluted EPS -$0.54

Aug 10

Current report 8-K

New debt or off-balance-sheet obligation, Regulation FD disclosure

Aug 10

Quarterly report 10-Q FY2023 Q2, ended Jul 1

Quarterly report for FY2023 Q2

Revenue $471.95M ▲ 6.5% Net income $25.6M Diluted EPS $0.13

Aug 4

Current report 8-K Events of Jul 31

Entered into a material agreement, Regulation FD disclosure

Jun 30

Earnings call

Q2 2023 earnings call

Jun 15

Current report 8-K Events of Jun 9

Director or officer change, or executive pay, Regulation FD disclosure

May 22

Current report 8-K

Regulation FD disclosure

May 12

Current report 8-K Events of May 10

Shareholder vote results

May 11

Earnings call

Q1 2023 earnings call